Anrecfen Injection Application Scope

Treatment of light to moderate pain after abdominal surgery in adults. Treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients undergoing maintenance hemodialysis.

Anrecfen Injection Characteristics

Ingredients: Anrecfen (HSK21542)
Properties: Clear, colorless injection solution.
Packaging Specification: 1ml:0.1mg.
Storage: Sealed, protected from light, in a cool place (not exceeding 25°C).
Expiry Date: As indicated on the packaging.
Executive Standard: As indicated on the packaging.
Approval Number: H20250014
Date of Revision: May 2025 (initial approval; revisions may follow new indications).
Manufacturer: Haisco Pharmaceutical Group Co., Ltd.

Guidelines for the Use of Anrecfen Injection

Dosage and Administration:
- Recommended Dose: 1.0 μg/kg body weight. Postoperatively, administer 1-3 times per day as needed, with an interval of at least 8 hours between doses. No dose adjustment required for elderly patients or those with hepatic impairment. For pruritus in CKD patients, similar dosing principles apply based on symptom severity.
- Administration: Dilute if necessary per clinical protocol; administer via IV push or infusion under medical supervision.
- Missed Dose: As this is an as-needed medication for pain or pruritus, there is no fixed schedule. Administer the next dose when symptoms recur, maintaining the minimum 8-hour interval.
Adverse Reactions:
- Common Adverse Reactions: Nausea (5.1%), vomiting (2.2%), decreased thyroid-stimulating hormone (TSH) levels (3.7%), headache, and diarrhea (incidence ≥1%).
- Serious Adverse Reactions: Rare, but may include hypersensitivity reactions or other unanticipated effects; monitor closely. No significant reports of respiratory depression or addiction in clinical data.
Contraindications: Known hypersensitivity to anrecfen or any excipients. Use with caution in patients with severe renal impairment not on dialysis (limited data).
Precautions:
- Monitor for signs of adverse reactions, particularly gastrointestinal effects. No dose adjustment needed for hepatic or mild renal impairment, but caution in severe cases. Not recommended during pregnancy or lactation without medical advice. Avoid concurrent use with central opioids if possible to prevent potential additive effects.

Anrecfen Injection Interactions

Low potential for drug interactions; anrecfen is minimally metabolized by the liver and does not induce or inhibit CYP450 enzymes at therapeutic doses. No significant interactions reported with common medications, but monitor when combined with other analgesics or antipruritics.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.